Wedbush Securities Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,200 shares of the company's stock after selling 2,359 shares during the quarter. Eli Lilly and Company comprises 0.5% of Wedbush Securities Inc.'s portfolio, making the stock its 23rd biggest position. Wedbush Securities Inc.'s holdings in Eli Lilly and Company were worth $14,050,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $8,407,908,000. Proficio Capital Partners LLC grew its stake in shares of Eli Lilly and Company by 100,387.1% in the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after buying an additional 5,197,038 shares in the last quarter. Wellington Management Group LLP increased its holdings in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after buying an additional 2,012,129 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Eli Lilly and Company during the fourth quarter worth $1,240,653,000. Finally, Parnassus Investments LLC grew its position in shares of Eli Lilly and Company by 38,959.8% in the 4th quarter. Parnassus Investments LLC now owns 934,702 shares of the company's stock valued at $721,590,000 after acquiring an additional 932,309 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Citigroup dropped their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Bank of America restated a "buy" rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $1,017.67.
Check Out Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
Eli Lilly and Company stock traded down $33.81 during mid-day trading on Wednesday, reaching $692.43. 2,495,956 shares of the company were exchanged, compared to its average volume of 3,345,566. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm has a market cap of $656.54 billion, a PE ratio of 58.99, a PEG ratio of 1.40 and a beta of 0.51. The company has a fifty day simple moving average of $843.43 and a 200-day simple moving average of $827.93.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.
Insider Buying and Selling at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company's stock.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
